drugset / Trial / NCT02049060
Study of the Combination of Tivantinib Plus Pemetrexed and Carboplatin
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, open-label, mono-centric, phase I-Ib trial of Tivantinib in combination with Pemetrexed and Carboplatin as first-line therapy in patients with advanced or metastatic cancer suitable for a Carboplatin and Pemetrexed regimen as part of their specific therapy.
Timeline
- Start
- 2013-01
- Primary completion
- 2016-05
- Completion
- 2017-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tivantinib | Small molecule | 120 mg | Oral |
| Subject | Tivantinib | Small molecule | 240 mg | Oral |
| Subject | Tivantinib | Small molecule | 360 mg | Oral |
| Background | Carboplatin | Small molecule | — | Intravenous |
| Background | Pemetrexed | Small molecule | 500 mg/m2 | Intravenous |